WINDOW consortium: A path towards increased therapy efficacy against glioblastoma

Kulsoom U. Abdul, Megan Houweling, Fredrik Svensson, Ravi S. Narayan, Fleur M.G. Cornelissen, Asli Küçükosmanoglu, Emmanouil Metzakopian, Colin Watts, David Bailey, Tom Wurdinger, Bart A. Westerman

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Glioblastoma is the most common and malignant form of brain cancer, for which the standard treatment is maximal surgical resection, radiotherapy and chemotherapy. Despite these interventions, mean overall survival remains less than 15 months, during which extensive tumor infiltration throughout the brain occurs. The resulting metastasized cells in the brain are characterized by chemotherapy resistance and extensive intratumoral heterogeneity. An orthogonal approach attacking both intracellular resistance mechanisms as well as intercellular heterogeneity is necessary to halt tumor progression. For this reason, we established the WINDOW Consortium (Window for Improvement for Newly Diagnosed patients by Overcoming disease Worsening), in which we are establishing a strategy for rational selection and development of effective therapies against glioblastoma. Here, we overview the many challenges posed in treating glioblastoma, including selection of drug combinations that prevent therapy resistance, the need for drugs that have improved blood brain barrier penetration and strategies to counter heterogeneous cell populations within patients. Together, this forms the backbone of our strategy to attack glioblastoma.

Original languageEnglish
Pages (from-to)17-24
Number of pages8
JournalDrug Resistance Updates
Volume40
DOIs
Publication statusPublished - 1 Sep 2018

Cite this

Abdul, Kulsoom U. ; Houweling, Megan ; Svensson, Fredrik ; Narayan, Ravi S. ; Cornelissen, Fleur M.G. ; Küçükosmanoglu, Asli ; Metzakopian, Emmanouil ; Watts, Colin ; Bailey, David ; Wurdinger, Tom ; Westerman, Bart A. / WINDOW consortium : A path towards increased therapy efficacy against glioblastoma. In: Drug Resistance Updates. 2018 ; Vol. 40. pp. 17-24.
@article{446f553b241c465693164dbf455b9873,
title = "WINDOW consortium: A path towards increased therapy efficacy against glioblastoma",
abstract = "Glioblastoma is the most common and malignant form of brain cancer, for which the standard treatment is maximal surgical resection, radiotherapy and chemotherapy. Despite these interventions, mean overall survival remains less than 15 months, during which extensive tumor infiltration throughout the brain occurs. The resulting metastasized cells in the brain are characterized by chemotherapy resistance and extensive intratumoral heterogeneity. An orthogonal approach attacking both intracellular resistance mechanisms as well as intercellular heterogeneity is necessary to halt tumor progression. For this reason, we established the WINDOW Consortium (Window for Improvement for Newly Diagnosed patients by Overcoming disease Worsening), in which we are establishing a strategy for rational selection and development of effective therapies against glioblastoma. Here, we overview the many challenges posed in treating glioblastoma, including selection of drug combinations that prevent therapy resistance, the need for drugs that have improved blood brain barrier penetration and strategies to counter heterogeneous cell populations within patients. Together, this forms the backbone of our strategy to attack glioblastoma.",
keywords = "Blood brain barrier, Combination therapy, Glioblastoma, Small molecule drugs, Therapy resistance, Toxicity",
author = "Abdul, {Kulsoom U.} and Megan Houweling and Fredrik Svensson and Narayan, {Ravi S.} and Cornelissen, {Fleur M.G.} and Asli K{\"u}{\cc}{\"u}kosmanoglu and Emmanouil Metzakopian and Colin Watts and David Bailey and Tom Wurdinger and Westerman, {Bart A.}",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.drup.2018.10.001",
language = "English",
volume = "40",
pages = "17--24",
journal = "Drug Resistance Updates",
issn = "1368-7646",
publisher = "Churchill Livingstone",

}

Abdul, KU, Houweling, M, Svensson, F, Narayan, RS, Cornelissen, FMG, Küçükosmanoglu, A, Metzakopian, E, Watts, C, Bailey, D, Wurdinger, T & Westerman, BA 2018, 'WINDOW consortium: A path towards increased therapy efficacy against glioblastoma' Drug Resistance Updates, vol. 40, pp. 17-24. https://doi.org/10.1016/j.drup.2018.10.001

WINDOW consortium : A path towards increased therapy efficacy against glioblastoma. / Abdul, Kulsoom U.; Houweling, Megan; Svensson, Fredrik; Narayan, Ravi S.; Cornelissen, Fleur M.G.; Küçükosmanoglu, Asli; Metzakopian, Emmanouil; Watts, Colin; Bailey, David; Wurdinger, Tom; Westerman, Bart A.

In: Drug Resistance Updates, Vol. 40, 01.09.2018, p. 17-24.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - WINDOW consortium

T2 - A path towards increased therapy efficacy against glioblastoma

AU - Abdul, Kulsoom U.

AU - Houweling, Megan

AU - Svensson, Fredrik

AU - Narayan, Ravi S.

AU - Cornelissen, Fleur M.G.

AU - Küçükosmanoglu, Asli

AU - Metzakopian, Emmanouil

AU - Watts, Colin

AU - Bailey, David

AU - Wurdinger, Tom

AU - Westerman, Bart A.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Glioblastoma is the most common and malignant form of brain cancer, for which the standard treatment is maximal surgical resection, radiotherapy and chemotherapy. Despite these interventions, mean overall survival remains less than 15 months, during which extensive tumor infiltration throughout the brain occurs. The resulting metastasized cells in the brain are characterized by chemotherapy resistance and extensive intratumoral heterogeneity. An orthogonal approach attacking both intracellular resistance mechanisms as well as intercellular heterogeneity is necessary to halt tumor progression. For this reason, we established the WINDOW Consortium (Window for Improvement for Newly Diagnosed patients by Overcoming disease Worsening), in which we are establishing a strategy for rational selection and development of effective therapies against glioblastoma. Here, we overview the many challenges posed in treating glioblastoma, including selection of drug combinations that prevent therapy resistance, the need for drugs that have improved blood brain barrier penetration and strategies to counter heterogeneous cell populations within patients. Together, this forms the backbone of our strategy to attack glioblastoma.

AB - Glioblastoma is the most common and malignant form of brain cancer, for which the standard treatment is maximal surgical resection, radiotherapy and chemotherapy. Despite these interventions, mean overall survival remains less than 15 months, during which extensive tumor infiltration throughout the brain occurs. The resulting metastasized cells in the brain are characterized by chemotherapy resistance and extensive intratumoral heterogeneity. An orthogonal approach attacking both intracellular resistance mechanisms as well as intercellular heterogeneity is necessary to halt tumor progression. For this reason, we established the WINDOW Consortium (Window for Improvement for Newly Diagnosed patients by Overcoming disease Worsening), in which we are establishing a strategy for rational selection and development of effective therapies against glioblastoma. Here, we overview the many challenges posed in treating glioblastoma, including selection of drug combinations that prevent therapy resistance, the need for drugs that have improved blood brain barrier penetration and strategies to counter heterogeneous cell populations within patients. Together, this forms the backbone of our strategy to attack glioblastoma.

KW - Blood brain barrier

KW - Combination therapy

KW - Glioblastoma

KW - Small molecule drugs

KW - Therapy resistance

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=85056211645&partnerID=8YFLogxK

U2 - 10.1016/j.drup.2018.10.001

DO - 10.1016/j.drup.2018.10.001

M3 - Article

VL - 40

SP - 17

EP - 24

JO - Drug Resistance Updates

JF - Drug Resistance Updates

SN - 1368-7646

ER -